Company Overview
Owlet, Inc. provides digital parenting solutions in the United States, the United Kingdom, and internationally. The company offers a digital parenting platform that provides real-time data and insights to parents. It also provides sock monitors, including Dream Sock, a wearable infant health monitor equipped with pulse oximetry technology that tracks vital signs, such as pulse rate, activity, oxygen level, and sleep patterns; BabySat, which is intended for infants with conditions, including respiratory syncytial virus, pneumonia, bronchitis, croup, and other diagnoses; and Dream Sight, an audio and video monitor that enables parents to monitor their child. In addition, the company offers Dream Duo, which integrates Dream Sock and Dream Sight to create a connected health and safety system; Owlet360, a subscription service that provides personalized understanding of the babies' development, health, and sleep trends; and accessories, such as fabric accessory socks and the Owlet Sock Travel Case. The company was founded in 2012 and is headquartered in Lehi, Utah.
Recent Developments
- Dec 2025 Revenue of $105.71M (+35.4% YoY); net profit $-39.68M.
- Trailing 12 Months Year-on-year growth — revenue +29.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.81% |
| 1 Year: | 29.90% |
Stock Price Performance
| 1 Year: | -35.07% |
| 6 Months: | -20.95% |
| 3 Months: | +3.97% |
| 1 Month: | -9.45% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.18 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 69.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OWLT Owlet, Inc. PHARMA | 4.98 | -16.60 | $145.52M | 0.00% | -19.96% | - | 8.81% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 21.17M | 21.91M | 24.94M | 31.50M | 21.54M | 18.35M | 17.36M | 10.74M | 13.09M | 9.18M | 14.75M | 20.70M | 22.12M | - | 21.10M | 26.06M | 31.99M | 26.55M | 22.46M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.78M | 12.68M | 15.79M | 13.93M | 10.22M |
| Gross Profit | - | - | 9.82M | 12.68M | 13.52M | 14.88M | 8.76M | 6.62M | 4.61M | 4.15M | 5.23M | 3.33M | 6.55M | 10.25M | 11.55M | - | 11.33M | 13.38M | 16.20M | 12.63M | 12.24M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.00M | 15.30M | 14.98M | 17.51M | 17.73M |
| Operating Income | - | - | -1.12M | -2.85M | -5.85M | -13.76M | -21.70M | -20.36M | -21.82M | -10.96M | -6.71M | -7.88M | -5.75M | -2.24M | -4.82M | - | -2.67M | -1.92M | 1.22M | -4.89M | -5.49M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.15M | -1.77M | 5.16M | -8.46M | -2.46M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.38M | 991.00K | - | 860.00K | 588.00K | 683.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.04M | -37.61M | 4.14M | -9.22M | -3.33M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.00K | 33.00K | 9.00K | -26.00K | 7.00K |
| Net Income | -2.13M | -1.09M | -1.50M | -7.86M | -5.33M | -34.46M | -28.76M | -11.72M | -19.36M | -11.87M | -8.47M | -5.64M | 3.27M | -1.15M | -5.61M | - | 3.02M | -37.65M | 4.13M | -9.19M | -3.34M |
| Diluted EPS | - | - | - | -0.35 | -0.24 | -0.36 | -0.26 | -1.48 | -2.42 | -1.54 | -1.19 | -0.84 | -0.51 | -0.30 | -0.61 | - | 0.11 | -2.37 | -0.06 | -0.39 | -0.25 |
| R&D Expense | - | - | 2.73M | 3.43M | 4.52M | 6.32M | 8.54M | 7.77M | 7.07M | 2.89M | 2.75M | 2.43M | 2.35M | 2.35M | 2.56M | - | 2.90M | 3.75M | 3.79M | - | 3.96M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 75.40M | - | 69.20M | 54.01M | 78.06M | 105.71M |
| Cost of Revenue | - | - | 45.89M | 31.42M | 38.75M | 52.17M |
| Gross Profit | 35.88M | - | 23.31M | 22.59M | 39.31M | 53.53M |
| Operating Expenses | - | - | 107.93M | 51.22M | 59.53M | 61.79M |
| Operating Income | -6.99M | - | -84.62M | -28.63M | -20.22M | -8.26M |
| EBITDA | - | - | -75.53M | -27.49M | -9.47M | -35.64M |
| Interest Expense | - | - | 1.10M | 3.19M | 1.63M | 3.42M |
| Pretax Income | - | - | -79.31M | -32.89M | -12.48M | -39.65M |
| Tax Provision | - | - | 29.00K | 10.00K | 54.00K | 28.00K |
| Net Income | -10.52M | - | -79.34M | -32.90M | -12.54M | -39.68M |
| Diluted EPS | -0.48 | - | -9.94 | -4.53 | -1.57 | -2.31 |
| R&D Expense | 10.46M | 21.43M | 27.90M | 10.35M | 9.80M | 14.08M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Jun 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 40.12M | - | 58.10M | 44.12M | 49.52M | 85.63M |
| Current Assets | - | - | - | - | 51.26M | 39.94M | 46.11M | 81.92M |
| Cash & Equivalents | - | - | 17.01M | - | 11.23M | 16.56M | 20.25M | 35.46M |
| Inventory | - | - | - | - | 18.52M | 6.49M | 10.52M | 15.29M |
| Receivables | - | - | - | - | 15.96M | 13.97M | 12.14M | 22.93M |
| Total Liabilities | - | - | 60.94M | - | 68.74M | 73.80M | 66.33M | 50.18M |
| Current Liabilities | - | - | 47.27M | - | 66.60M | 45.09M | 36.43M | 44.24M |
| Long Term Debt | - | - | 10.18M | 7.99M | - | - | 4.33M | 2.46M |
| Total Debt | - | - | - | - | 16.20M | 15.19M | 11.70M | 13.03M |
| Total Equity | -58.90M | 0 | -68.01M | - | -10.63M | -29.68M | -16.81M | 35.45M |
| Shares Outstanding | - | - | - | - | 8.24M | 8.80M | 15.73M | 26.95M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -129.00K | -40.56M | -81.38M | -23.53M | -11.21M | -10.79M |
| Investing Cash Flow | -1.06M | -2.02M | -1.56M | -59.00K | -761.00K | -943.00K |
| Financing Cash Flow | 6.46M | 120.62M | -878.00K | 28.91M | 16.04M | 32.12M |
| Capital Expenditure | -967.00K | -969.00K | -1.56M | -59.00K | -761.00K | -943.00K |
| Free Cash Flow | -1.10M | -41.52M | -82.94M | -23.59M | -11.97M | -11.73M |
| Net Change in Cash | - | - | -83.82M | 5.33M | 4.07M | 20.38M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 47.6% | - | 33.7% | 41.8% | 50.4% | 50.6% |
| Operating Margin % | -9.3% | - | -122.3% | -53.0% | -25.9% | -7.8% |
| Net Margin % | -14.0% | - | -114.6% | -60.9% | -16.1% | -37.5% |
| ROE % | 15.5% | - | 746.0% | 110.9% | 74.6% | -111.9% |
| ROCE % | 97.7% | - | 995.8% | 2,960.9% | -154.5% | -20.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Eclipse Operations, LLC | 26.35% | 7.70M | $36.50M |
| 2 | Granahan Investment Management LLC | 5.46% | 1.60M | $7.56M |
| 3 | Cannell Capital LLC | 4.22% | 1.23M | $5.85M |
| 4 | AWM Investment Company, Inc. | 4.19% | 1.23M | $5.81M |
| 5 | Vanguard Capital Management LLC | 2.74% | 801.72K | $3.80M |
| 6 | Ameriprise Financial, Inc. | 1.75% | 512.65K | $2.43M |
| 7 | Harbor Capital Advisors, Inc. | 1.13% | 329.94K | $1.56M |
| 8 | Blackrock Inc. | 1.13% | 329.88K | $1.56M |
| 9 | Jacobs Levy Equity Management, Inc. | 1.13% | 330.82K | $1.57M |
| 10 | Meros Investment Management, Lp | 1.12% | 327.11K | $1.55M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OWLT
Owlet: The Business Is Growing, But The Stock Isn’t (NYSE:OWLT) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQSDk2c1BUQVdhSnhmT2VQOEhlVDhaR3M5aE41MjAzTFpoOWVNd3c5cDJGVkhjVS1tcUd1dUlmeWY2QkhqTnF4MDlGTVc3QzhoVldhSndRWm5tTzJfSWpwMnFGVkJZa01udENKa25qQVdYWklYYVRsRjg2LTdHRExrVHMxV1ZwV3VUVnN4aV…
The Technical Signals Behind (OWLT) That Institutions Follow - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNOGd4cDJOOFRkeDYtcWNtTllXc3Jkb191bmhSc0tRaGFRZW9BU19OdnFQd3hDUjkteXoySU5aMlJTVF9RQzRWVjRrMGRBZGN1QVdPbWpuZ2U4blUxelpMUU9MNUQ0czF3SU1PalQ2aG5ZZjd4SUVKZUNwdGFnOEF2cVFwdlZNUXB0Y1JNVU…
Owlet, Inc. (OWLT) Q2 Earnings and Revenues Beat Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPWG1NSVJlWFkzdlpFSjV5U2g3bEM4cXd4eGRUWk1KckY0NENsMUJaRVVHeEJRNUJhUUR4VHBoWFFXdjhJOGcwVkZRLTM1dTdnaXdFZUJrRG9oZUR2eEdTWjBNTlU5Q1oydllCVmNSUVo5QjlmU2hfdm5VVEFrYVJxMlY5QVBQaXpZemJFVX…
Owlet (OWLT) insider reports new stock transactions - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPSUJmcldVRlhjbkpPN19KME1wRlhjaVQxZndVSEF3a2JMandkcU9oZmZiWGhZQnltR2lTLWRTUzVCeXJ1SEt3dWxZREo2UGZqTUc1TURRNjlfam1iTUI1blVLbjZKa0NncXE2dXpyNEtDU3BCOUFMOVpVcjBaaWI1eUR3em5va2lSZUlLci…
$OWLT stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQVXoxSjVoNVBfTkZ6ODZXWHlCM1JxU0M0SWd3aEprTXhaR3l3elBQYTlPUnE2Z21rX2dUcTFzWEtQZFdWLW5IYm50M0Z4S285WkFFQVRPVXpzamxBelJ4bWRJQS1yZzdqcnMxMXAzMS1SdzdJODNfT1J6d3pmUXY0VFFSc3U5TzRXci1ITn…
Owlet (OWLT) Stock Climbs As Subscription Growth Sharpens Turnaround Focus - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE9kT0xySTE3SGNENVdES0tMaW1UNXJpTUEzVUQtVGlKR0FOWEZWOE93VUpEcHNZeWh5blVYR0N3ZWhsTmh4a1JwNVlYa1FtYXNGS1dtS25tTDg?oc=5" target="_blank">Owlet (OWLT) Stock Climbs As Subscription Growth…
OWLT — Frequently Asked Questions
What is the current share price of Owlet, Inc. (OWLT)?
As of 2026-09-19 21:16 PDT, Owlet, Inc. (OWLT) trades at $4.98 on NYSE. Its 52-week range is $4.44 to $16.52.
What is the market capitalisation of OWLT?
Owlet, Inc. (OWLT) has a market capitalisation of $145.52M on NYSE.
What is the P/E ratio of OWLT?
OWLT trades at a trailing price-to-earnings (P/E) ratio of -16.60. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.90.
Is OWLT a good stock to buy?
This page provides a data-driven analysis of Owlet, Inc. (OWLT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.